Tauklarify Tau PET vs Alzheimer's Blood Tests in 2026 means this: blood tests now offer first-step triage in primary care, while tau PET stages disease in specialty care. Tauklarify (florquinitau F 18 injection, formerly MK-6240) is a brain PET tracer that lights up tau neurofibrillary tangles linked to Alzheimer's. For primary-care patients with memory complaints, the news does not mean everyone needs a scan. A blood test can often rule out Alzheimer's pathology first, and PET follows only when results will change care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Tauklarify show?
- Where do blood tests fit first?
- Who should get which test?
- What should you ask at your visit?
What does Tauklarify show?
Tauklarify was approved for brain PET in cognitively impaired adults evaluated for Alzheimer's to identify tau tangle pathology, according to the FDA approval notice in Novel Drug Approvals for 2026. Lantheus announced the approval on Aug. 14, 2026. It does not diagnose Alzheimer's alone.
Approval rested on two blinded-read studies with 617 participants and five independent readers, according to Pharmacy Times in its approval summary. Positive agreement was 68%-88% and negative agreement was 93%-99%, with strong reliability between readers. In practice, tau PET shows spread and severity. That staging helps guide eligibility and monitoring for disease-modifying therapies, when specialty doctors consider them.
Where do blood tests fit first?
Blood tests are cheaper and more accessible. They work best as triage to rule out Alzheimer's pathology before PET or spinal-fluid testing. Fujirebio's Lumipulse G pTau217/beta-Amyloid 1-42 plasma ratio, cleared May 16, 2025, was the first cleared blood test for symptomatic adults age 55 and older in specialty care. It showed about 92% positive and 97% negative agreement with amyloid status. Roche's Elecsys pTau181, cleared Oct.
13, 2025 with Eli Lilly, became the first test for primary-care initial assessment in adults 55 and older with cognitive complaints, with 97.9% negative predictive value in 312 patients as a rule-out test. By late Aug. 2026, four amyloid blood tests were cleared, according to MedTech Dive in its coverage of the Roche and Lilly clearance. The newer entries included C2N PrecivityAD2 on Aug. 20, 2026 for ages 40 and older and Roche/Lilly Elecsys pTau217 on Aug. 24, 2026 as a single-marker rule-in/rule-out test for primary and specialty care.
Who should get which test?
The Alzheimer's Association guideline from July 29, 2025 limits blood-biomarker use to patients with objective impairment seen in specialty care. Tests with at least 90% sensitivity and 75% specificity may triage out disease. Tests with at least 90% sensitivity and 90% specificity may replace PET or spinal-fluid confirmation. That distinction matters for primary-care patients.
A high-quality negative blood test can reduce the need for referral testing. A positive or borderline result still needs specialty review. No cleared blood test is for asymptomatic screening. Testing without symptoms, family risk alone, or worry alone is not an approved use.
What should you ask at your visit?
Start with symptoms, timing, and daily impact. Bring examples of missed bills, lost words, or getting lost in familiar places. Ask whether your clinic offers objective cognitive testing.
Useful questions and steps include: Know the limits before you decide. Tauklarify was validated mainly in amyloid-negative unimpaired people versus amyloid-positive impaired people, so a negative scan does not exclude tau pathology and a positive scan does not alone prove Alzheimer's. Bring your medication list, sleep history, and a family member who sees your daily function.
- Is my impairment measurable on exam, not only self-reported?
- Am I eligible for an approved blood test for initial assessment?
- Does a negative result rule out referral, or do I still need specialty care?
- If Alzheimer's pathology is likely, would tau PET affect treatment choice?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Primary Care Patients Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Primary Care Patients Should Know About the News
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
